This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages without signing in

NICE guidance - infliximab for the treatment for adults with psoriasis

Authoring team

  • Summary features of the NICE guidance are outlined below (1):
    • infliximab, within its licensed indications, is recommended as a treatment option for adults with plaque psoriasis only when the following criteria are met
      • the disease is very severe as defined by a total Psoriasis Area Severity Index (PASI) of 20 or more and a Dermatology Life Quality Index (DLQI) of more than 18
      • the psoriasis has failed to respond to standard systemic therapies such as ciclosporin, methotrexate or PUVA (psoralen and long-wave ultraviolet radiation), or the person is intolerant to or has a contraindication to these treatments
    • infliximab treatment should be continued beyond 10 weeks only in people whose psoriasis has shown an adequate response to treatment within 10 weeks. An adequate response is defined as either:
      • a 75% reduction in the PASI score from when treatment started (PASI 75) or
      • a 50% reduction in the PASI score (PASI 50) and a five-point reduction in the DLQI from when treatment started

For more detailed information see full guidance (1).

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.